Loading stock data…
$5.92-0.27 (-4.36%)
Solid Biosciences Inc.
Solid Biosciences Inc. in the Healthcare sector is trading at $5.92 with a market capitalization of $736M. Wall Street consensus targets $18.71 (14 analysts), implying a +216.1% move over the next 12 months. The stock is currently 48% below its 52-week high of $11.45, remaining 22.5% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$57.38M↓ | -$57.31M↓ | -$49.40M↓ | -$48.06M↓ | -$41.69M |
| Net Income | -$54.80M↑ | -$56.74M↓ | -$49.79M↓ | -$45.78M↓ | -$39.48M |
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for th...